Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).

Frederick L. Locke H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL info_outline Frederick L. Locke, Lazaros J. Lekakis, Herbert Eradat, Javier Munoz, Michael Timothy Tees, Sven de Vos, Rajneesh Nath, Don A. Stevens, Shahbaz Malik, Leslie Popplewell, Mehdi Hamadani, Olalekan O. Oluwole, Miguel-Angel Perales, David Bernard Miklos, Paul Fisher, Lovely Goyal, Gregory Kaufman, Kazuharu Kai, Arun Balakumaran, Sattva Swarup Neelapu

Authors Frederick L. Locke H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL info_outline Frederick L. Locke, Lazaros J. Lekakis, Herbert Eradat, Javier Munoz, Michael Timothy Tees, Sven de Vos, Rajneesh Nath, Don A. Stevens, Shahbaz Malik, Leslie Popplewell, Mehdi Hamadani, Olalekan O. Oluwole, Miguel-Angel Perales, David Bernard Miklos, Paul Fisher, Lovely Goyal, Gregory Kaufman, Kazuharu Kai, Arun Balakumaran, Sattva Swarup Neelapu Organizations H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, University of Miami Sylvester Cancer Center, Miami, FL, Ronald Reagan UCLA Medical Center, Los Angeles, CA, Mayo Clinic Comprehensive Cancer Center, Phoenix, AZ, Colorado Blood Cancer Institute, Denver, CO, University of California Los Angeles, Los Angeles, CA, Banner Health Center, Gilbert, AZ, Norton Cancer Institute, Louisville, KY, Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center, Austin, TX, City of Hope National Medical Center, Duarte, CA, Medical College of Wisconsin, Milwaukee, WI, Vanderbilt University Medical Center, Nashville, TN, Memorial Sloan Kettering Cancer Center, New York, NY, Stanford University, Stanford, CA, Allogene Therapeutics, South San Francisco, CA, University of Texas MD Anderson Cancer Center, Houston, TX Abstract Disclosures Research Funding Pharmaceutical/Biotech Company Allogene Therapeutics Background: Approximately 50% to 60% of pts with r/r LBCL will either not achieve a complete response (CR) or will relapse with current treatments and require additional therapy. Autologous anti-CD19 chimeric antigen receptor T (CAR T) therapies have revolutionized the care of patients whose disease progresses following standard therapies, but patient-specific manufacturing processes and long wait times to treatment present challenges for their broad clinical use. Allogeneic (healthy-donor-derived), off-the-shelf, anti-CD19 (CAR T) treatment promises broader and more rapid access to one-dose treatment with curative intent. Initial phase 1 data for the anti-CD19 AlloCAR T cell product ALLO-501 (NCT03939026) and successor, ALLO-501A (NCT04416984), demonstrated a manageable safety profile with no dose-limiting toxicities (DLTs), and efficacy comparable to autologous CAR T therapy in pts with r/r LBCL who were autologous CAR T-naïve. This update provides additional follow up and a focus on participants who received the conditioning regimen and cells made with an optimized manufacturing process currently under study in the first potentially pivotal trial for an allogeneic CAR T product. Methods: In these two multicenter, single-arm, open-label, phase 1 trials, a cohort of autologous CAR T-naïve pts with r/r LBCL underwent 3-day lymphodepletion (LD) with FCA90, fludarabine (F, 30 mg/m 2 /day), cyclophosphamide (C, 300 mg/m 2 /day), and ALLO-647 (A [anti-CD 52 mAb] 30 mg/day; total dose: 90 mg) followed by a single dose of ALLO-501 or ALLO-501A produced by the Alloy manufacturing process. Results: As of Jan 26, 2023, 12 pts received the FCA90 LD regimen and CAR T therapy with 100% receiving product per specifications with a median time from enrollment to LD of 3 days. Median follow-up time (actual) was 7.1 months (range: 1.4, 36.0). No DLTs, severe (Gr3+) cytokine-release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD) events occurred. An overall response rate and a CR rate of 66.7% and 58.3%, respectively, were observed. Median DOR was 23.1 months. Among 8 pts with the opportunity to be followed for 6 months, 5 (62.5%) had achieved CR and 4 (50.0%) sustained CR through 6 months. Analyses of vector copy number pharmacokinetics at Days 28 and 56 documented substantial and sustained expansion of CAR T cells. Conclusions: A one-time dose of allogeneic CAR T therapy following LD with FCA90 provided durable responses with a manageable safety profile in patients with r/r/ LBCL comparable to those treated with autologous CAR T cells. This treatment enables rapid access to off-the-shelf treatment with a median time from trial enrollment to treatment of 3 days. These findings support broader evaluation of ALLO-501A in the ongoing, first potentially pivotal phase 2 trial (ALPHA2) of off-the-shelf allogeneic CAR T cells. Clinical trial information: NCT03939026.

Clinical